According to filings with the U.S. Securities and Exchange Commission, Secretome Therapeutics has raised $30 Million in new Series A funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the current round of funding include: RA Capital Management, LP.

About Secretome Therapeutics
Secretome Therapeutics is a clinical-stage biotechnology company focused on developing investigational therapies derived from neonatal cardiac progenitor cells (nCPCs) to treat serious cardiovascular diseases, including heart failure, dilated cardiomyopathy, and heart failure with preserved ejection fraction. Using a proprietary platform that leverages the regenerative and immunomodulatory properties of neonatal cardiac-derived cells, the company aims to address significant unmet medical needs in cardiomyopathy and heart failure by activating the bodys natural repair mechanisms. Its lead product, STM-01, is an nCPC-based cellular therapy, and the company is also advancing STM-21, a secretome-based biologic derived from the same neonatal sources, both designed as off-the-shelf treatments with near-zero variability. Secretome Therapeutics emphasizes the use of neonatal tissue (from babies under 30 days old) to produce consistent, scalable products for clinical use and notes an early-stage pipeline targeting heart failure with preserved ejection fraction and dilated cardiomyopathy. Headquartered across facilities in Baltimore, Chicago, and Plano, the company positions itself at the forefront of next-generation regenerative cardiology by pioneering nCPC-based and secretome-based therapeutics for patients with high unmet medical need.

To learn more, visit https://secretometherapeutics.com/
Linkedin: https://www.linkedin.com/company/secretometx/

Contact:
Vinny Jindal, President and Chief Executive Officer
https://www.linkedin.com/in/vinny-jindal-4b9a3b8/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.